Additionally, recent studies have shown that combining FLT3i with PDP1 inhibition reduces OXPHOS activity and enhances AML sensitivity to FLT3i, further supporting the promise of combination therapies targeting metabolic vulnerabilities in FLT3-mutated AML. Here, FLT3 is linked to acute myeloid leukemia.